News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Much Biogen (BIIB)'s Top-Selling MS Drug Sales Could Fall by 2020



4/10/2017 5:52:43 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Annual revenue from Biogen’s multiple sclerosis treatments could decline $900 million by 2020 — more than 10 percent — amid increased competition from Roche’s potential blockbuster Ocrevus and other drugs, according to an analyst.

Leerink Partners analyst Geoffrey Porges made the prediction in a note on Friday morning, citing conversations with physicians at large MS treatment centers who collectively oversee more than 16,000 patients, some of whom take drugs sold by Biogen (Nasdaq: BIIB).

According to Porges, the specialists indicated that Ocrevus, which was approved by the FDA on March 28, will primarily cut into sales of Biogen’s Tysabri and its top-selling drug Tecfidera.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES